Dr. Lal Pathlabs is currently trading at Rs. 2077.40, up by 17.35 points or 0.84% from its previous closing of Rs. 2060.05 on the BSE.
The scrip opened at Rs. 2089.95 and has touched a high and low of Rs. 2089.95 and Rs. 2038.95 respectively. So far 778 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 10 has touched a 52 week high of Rs. 3270.30 on 02-Feb-2022 and a 52 week low of Rs. 1805.10 on 26-May-2022.
Last one week high and low of the scrip stood at Rs. 2117.65 and Rs. 2025.00 respectively. The current market cap of the company is Rs. 17177.15 crore.
The promoters holding in the company stood at 55.05%, while Institutions and Non-Institutions held 31.99% and 12.96% respectively.
Dr. Lal Pathlabs’ Wholly Owned Subsidiary— PathLabs Unifiers (PUPL) has received approval for the acquisition of further 10% equity stake in its Subsidiary Company i.e. APRL PathLabs (APRL). Object of acquisition is to strengthen the company’s presence in the state of Gujarat, India.
Cost of acquisition is around Rs 7.50 Million. Post this acquisition, total equity stake of PUPL in APRL will increase from 70% to 80%. The Board of Directors of the company in their meeting held on January 30, 2023 approved the same.
Dr. Lal Pathlabs is a provider of diagnostic and related healthcare tests and services in India.